메뉴 건너뛰기




Volumn 13, Issue 11, 2014, Pages 1483-1499

Safety of antiandrogen therapy for treating prostate cancer

Author keywords

Adverse events; Antiandrogens; ARN 509; Bicalutamide; Enzalutamide; Flutamide nilutamide; Prostate cancer; Tolerability

Indexed keywords

4 [7 [6 CYANO 5 (TRIFLUOROMETHYL) 3 PYRIDINYL] 8 OXO 6 THIOXO 5,7 DIAZASPIRO[3.4]OCTAN 5 YL] 2 FLUORO N METHYLBENZAMIDE; ABIRATERONE ACETATE; ANTIANDROGEN; BICALUTAMIDE; ENZALUTAMIDE; FLUTAMIDE; NILUTAMIDE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

EID: 84914694627     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2014.966686     Document Type: Review
Times cited : (23)

References (99)
  • 2
    • 79954428605 scopus 로고    scopus 로고
    • Impact of comorbidity on survival among men with localized prostate cancer
    • Albertsen PC, Moore DF, Shih W, et al. Impact of comorbidity on survival among men with localized prostate cancer. J ClinOncol 2011;29(10):1335-41
    • (2011) J ClinOncol , vol.29 , Issue.10 , pp. 1335-1341
    • Albertsen, P.C.1    Moore, D.F.2    Shih, W.3
  • 3
    • 0037014792 scopus 로고    scopus 로고
    • Overdiagnosis due to prostate-specific antigen screening: Lessons from U.S. Prostate cancer incidence trends
    • Etzioni R, Penson DF, Legler JM, et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 2002;94(13):981-90
    • (2002) J Natl Cancer Inst , vol.94 , Issue.13 , pp. 981-990
    • Etzioni, R.1    Penson, D.F.2    Legler, J.M.3
  • 4
    • 70349231253 scopus 로고    scopus 로고
    • Contemporary risk profile of prostate cancer in the United States
    • Shao YH, Demissie K, Shih W, et al. Contemporary risk profile of prostate cancer in the United States. J Natl Cancer Inst 2009;101(18):1280-3
    • (2009) J Natl Cancer Inst , vol.101 , Issue.18 , pp. 1280-1283
    • Shao, Y.H.1    Demissie, K.2    Shih, W.3
  • 5
    • 2942677245 scopus 로고    scopus 로고
    • The changing face of low-risk prostate cancer: Trends in clinical presentation and primary management
    • Cooperberg MR, Lubeck DP, Meng MV, et al. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol 2004;22:2141-9
    • (2004) J Clin Oncol , vol.22 , pp. 2141-2149
    • Cooperberg, M.R.1    Lubeck, D.P.2    Meng, M.V.3
  • 6
    • 39149085396 scopus 로고    scopus 로고
    • Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: Long-term results of RTOG 8610
    • Roach M III, Bae K, Speight J, et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol 2008;26(4):585-91
    • (2008) J Clin Oncol , vol.26 , Issue.4 , pp. 585-591
    • Roach, M.1    Bae, K.2    Speight, J.3
  • 7
    • 0642311912 scopus 로고    scopus 로고
    • Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group Protocol 92-02
    • Hanks GE, Pajak TF, Porter A, et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 2003;21(21):3972-8
    • (2003) J Clin Oncol , vol.21 , Issue.21 , pp. 3972-3978
    • Hanks, G.E.1    Pajak, T.F.2    Porter, A.3
  • 8
    • 16344385883 scopus 로고    scopus 로고
    • Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase III RTOG 85-31
    • Pilepich MV, Winter K, Lawton CA, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005;61(5):1285-90
    • (2005) Int J Radiat Oncol Biol Phys , vol.61 , Issue.5 , pp. 1285-1290
    • Pilepich, M.V.1    Winter, K.2    Lawton, C.A.3
  • 9
    • 33646866593 scopus 로고    scopus 로고
    • Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy
    • Messing EM, Manola J, Yao J, et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006;7(6):472-9
    • (2006) Lancet Oncol , vol.7 , Issue.6 , pp. 472-479
    • Messing, E.M.1    Manola, J.2    Yao, J.3
  • 10
    • 84880002079 scopus 로고    scopus 로고
    • Recent trends in prostate cancer incidence by age, cancer stage, and grade, the United States, 2001-2007
    • Li J, Djenaba JA, Soman A, et al. Recent trends in prostate cancer incidence by age, cancer stage, and grade, the United States, 2001-2007. Prostate Cancer 2012;2012:691380
    • (2012) Prostate Cancer , vol.2012 , pp. 691380
    • Li, J.1    Djenaba, J.A.2    Soman, A.3
  • 11
    • 84874965010 scopus 로고    scopus 로고
    • Luteinizing hormone-releasing hormone agonists for the treatment of prostate cancer: 2012
    • Lepor H, Shore ND. Luteinizing hormone-releasing hormone agonists for the treatment of prostate cancer: 2012. Rev Urol 2012;14(1-2):1-12
    • (2012) Rev Urol , vol.14 , Issue.1-2 , pp. 1-12
    • Lepor, H.1    Shore, N.D.2
  • 12
    • 29144508739 scopus 로고    scopus 로고
    • Secondary hormonal therapy for advanced prostate cancer
    • Lam JS, Leppert JT, Vemulapalli SN, et al. Secondary hormonal therapy for advanced prostate cancer. J Urol 2006;175(1):27-34
    • (2006) J Urol , vol.175 , Issue.1 , pp. 27-34
    • Lam, J.S.1    Leppert, J.T.2    Vemulapalli, S.N.3
  • 13
    • 84862767296 scopus 로고    scopus 로고
    • Gonadotropin-releasing hormone: An update review of the antagonists versus agonists
    • Van Poppel H, Klotz L. Gonadotropin-releasing hormone: an update review of the antagonists versus agonists. Int J Urol 2012;19(7):594-601
    • (2012) Int J Urol , vol.19 , Issue.7 , pp. 594-601
    • Van Poppel, H.1    Klotz, L.2
  • 14
    • 84891809097 scopus 로고    scopus 로고
    • EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer
    • Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2014;65(2):467-79
    • (2014) Eur Urol , vol.65 , Issue.2 , pp. 467-479
    • Heidenreich, A.1    Bastian, P.J.2    Bellmunt, J.3
  • 15
    • 84909956498 scopus 로고    scopus 로고
    • Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists
    • Klotz L, Miller K, Crawford ED, et al. Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists. Eur Urol 2014, pii: S0302-2838(13)01491-7
    • (2014) Eur Urol , vol.13 , pp. 01491-01497
    • Klotz, L.1    Miller, K.2    Crawford, E.D.3
  • 16
    • 82655181898 scopus 로고    scopus 로고
    • Structural basis for nuclear hormone receptor DNA binding
    • Helsen C, Kerkhofs S, Clinckemalie L, et al. Structural basis for nuclear hormone receptor DNA binding. Mol Cell Endocrinol 2012;348(2):411-17
    • (2012) Mol Cell Endocrinol , vol.348 , Issue.2 , pp. 411-417
    • Helsen, C.1    Kerkhofs, S.2    Clinckemalie, L.3
  • 17
    • 77953027535 scopus 로고    scopus 로고
    • The rules of DNA recognition by the androgen receptor
    • Denayer S, Helsen C, Thorrez L, et al. The rules of DNA recognition by the androgen receptor. Mol Endocrinol 2010;24(5):898-913
    • (2010) Mol Endocrinol , vol.24 , Issue.5 , pp. 898-913
    • Denayer, S.1    Helsen, C.2    Thorrez, L.3
  • 18
    • 77951903529 scopus 로고    scopus 로고
    • The promise of novel androgen receptor antagonists
    • Gioeli DG. The promise of novel androgen receptor antagonists. Cell Cycle 2010;9(3):440-1
    • (2010) Cell Cycle , vol.9 , Issue.3 , pp. 440-441
    • Gioeli, D.G.1
  • 19
    • 33750321363 scopus 로고    scopus 로고
    • Antiandrogen treatments in locally advanced prostate cancer: Are they all the same?
    • Gillatt D. Antiandrogen treatments in locally advanced prostate cancer: are they all the same? J Cancer Res Clin Oncol 2006;132(Suppl 1):S17-26
    • (2006) J Cancer Res Clin Oncol , vol.132
    • Gillatt, D.1
  • 20
    • 49249119358 scopus 로고    scopus 로고
    • Maintenance of intratumoral androgens in metastatic prostate cancer: A mechanism for castration-resistant tumor growth
    • Montgomery RB, Mostaghel EA, Vessella R, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 2008;68:4447-54
    • (2008) Cancer Res , vol.68 , pp. 4447-4454
    • Montgomery, R.B.1    Mostaghel, E.A.2    Vessella, R.3
  • 21
    • 34250331066 scopus 로고    scopus 로고
    • Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: Therapeutic implications for castration-resistant prostate cancer
    • Mostaghel EA, Page ST, Lin DW, et al. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res 2007;67(10):5033-41
    • (2007) Cancer Res , vol.67 , Issue.10 , pp. 5033-5041
    • Mostaghel, E.A.1    Page, S.T.2    Lin, D.W.3
  • 23
    • 0035321536 scopus 로고    scopus 로고
    • Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: A systematic review
    • Schmitt B, Wilt TJ, Schellhammer PF, et al. Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: a systematic review. Urology 2001;57(4):727-32
    • (2001) Urology , vol.57 , Issue.4 , pp. 727-732
    • Schmitt, B.1    Wilt, T.J.2    Schellhammer, P.F.3
  • 24
    • 68149180921 scopus 로고    scopus 로고
    • Twenty years of controversy surrounding combined androgen blockade for advanced prostate cancer
    • Moul JW. Twenty years of controversy surrounding combined androgen blockade for advanced prostate cancer. Cancer 2009;115:3376-8
    • (2009) Cancer , vol.115 , pp. 3376-3378
    • Moul, J.W.1
  • 25
    • 0028022537 scopus 로고
    • Endocrine profiles during administration of the new non-steroidal anti-androgen Casodex in prostate cancer
    • Verhelst J, Denis L, Van Vliet P, et al. Endocrine profiles during administration of the new non-steroidal anti-androgen Casodex in prostate cancer. Clin Endocrinol (Oxf) 1994;41(4):525-30
    • (1994) Clin Endocrinol (Oxf) , vol.41 , Issue.4 , pp. 525-530
    • Verhelst, J.1    Denis, L.2    Van Vliet, P.3
  • 26
    • 79957865124 scopus 로고    scopus 로고
    • Bicalutamide monotherapy preserves bone mineral density, muscle strength and has significant health-related quality of life benefits for osteoporotic men with prostate cancer
    • Wadhwa VK, Weston R, Parr NJ. Bicalutamide monotherapy preserves bone mineral density, muscle strength and has significant health-related quality of life benefits for osteoporotic men with prostate cancer. BJU Int 2011;107(12):1923-9
    • (2011) BJU Int , vol.107 , Issue.12 , pp. 1923-1929
    • Wadhwa, V.K.1    Weston, R.2    Parr, N.J.3
  • 28
    • 0034603826 scopus 로고    scopus 로고
    • Single-therapy androgen suppression in men with advanced prostate cancer: A systematic review and meta-analysis
    • Seidenfeld J, Samson DJ, Hasselblad V, et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med 2000;132(7):566-77
    • (2000) Ann Intern Med , vol.132 , Issue.7 , pp. 566-577
    • Seidenfeld, J.1    Samson, D.J.2    Hasselblad, V.3
  • 29
    • 0033026221 scopus 로고    scopus 로고
    • Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: Results of an Italian Prostate Cancer Project study
    • Boccardo F, Rubagotti A, Barichello M, et al. Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study. J Clin Oncol 1999;17(7):2027-38
    • (1999) J Clin Oncol , vol.17 , Issue.7 , pp. 2027-2038
    • Boccardo, F.1    Rubagotti, A.2    Barichello, M.3
  • 30
    • 0033782359 scopus 로고    scopus 로고
    • Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup
    • Iversen P, Tyrrell CJ, Kaisary AV, et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. J Urol 2000;164(5):1579-82
    • (2000) J Urol , vol.164 , Issue.5 , pp. 1579-1582
    • Iversen, P.1    Tyrrell, C.J.2    Kaisary, A.V.3
  • 31
    • 0031798627 scopus 로고    scopus 로고
    • A randomised comparison of Casodex (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer
    • Tyrrell CJ, Kaisary AV, Iversen P, et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol 1998;33(5):447-56
    • (1998) Eur Urol , vol.33 , Issue.5 , pp. 447-456
    • Tyrrell, C.J.1    Kaisary, A.V.2    Iversen, P.3
  • 32
    • 84873861022 scopus 로고    scopus 로고
    • Androgen receptor antagonists in castration-resistant prostate cancer
    • Rathkopf D, Scher HI. Androgen receptor antagonists in castration-resistant prostate cancer. Cancer J 2013;19(1):43-9
    • (2013) Cancer J , vol.19 , Issue.1 , pp. 43-49
    • Rathkopf, D.1    Scher, H.I.2
  • 33
    • 84866770294 scopus 로고    scopus 로고
    • Increased survival with enzalutamide in prostate cancer after chemotherapy
    • Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367(13):1187-97.
    • (2012) N Engl J Med , vol.367 , Issue.13 , pp. 1187-1197
    • Scher, H.I.1    Fizazi, K.2    Saad, F.3
  • 34
    • 84891538656 scopus 로고    scopus 로고
    • Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer
    • Rathkopf DE, Morris MJ, Fox JJ, et al. Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer. J Clin Oncol 2013;31(28):3525-30.
    • (2013) J Clin Oncol , vol.31 , Issue.28 , pp. 3525-3530
    • De Rathkopf1    Morris, M.J.2    Fox, J.J.3
  • 35
    • 79957443342 scopus 로고    scopus 로고
    • Abiraterone and increased survival in metastatic prostate cancer
    • de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364(21):1995-2005
    • (2011) N Engl J Med , vol.364 , Issue.21 , pp. 1995-2005
    • De Bono, J.S.1    Logothetis, C.J.2    Molina, A.3
  • 36
    • 68949094223 scopus 로고    scopus 로고
    • Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer
    • Attard G, Reid AH, A'Hern R, et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 2009;27(23):3742-8
    • (2009) J Clin Oncol , vol.27 , Issue.23 , pp. 3742-3748
    • Attard, G.1    Reid, A.H.2    A'Hern, R.3
  • 37
    • 3042784503 scopus 로고    scopus 로고
    • Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer
    • O'Donnell A, Judson I, Dowsett M, et al. Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer 2004;90(12):2317-25
    • (2004) Br J Cancer , vol.90 , Issue.12 , pp. 2317-2325
    • O'Donnell, A.1    Judson, I.2    Dowsett, M.3
  • 38
    • 84872078210 scopus 로고    scopus 로고
    • Abiraterone in metastatic prostate cancer without previous chemotherapy
    • Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013;368(2):138-48
    • (2013) N Engl J Med , vol.368 , Issue.2 , pp. 138-148
    • Ryan, C.J.1    Smith, M.R.2    De Bono, J.S.3
  • 39
    • 84856774377 scopus 로고    scopus 로고
    • Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer
    • Attard G, Reid AH, Auchus RJ, et al. Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer. J Clin Endocrinol Metab 2012;97(2):507-16
    • (2012) J Clin Endocrinol Metab , vol.97 , Issue.2 , pp. 507-516
    • Attard, G.1    Reid, A.H.2    Auchus, R.J.3
  • 40
    • 84908450155 scopus 로고    scopus 로고
    • Enzalutamide in metastatic prostate cancer before chemotherapy
    • Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014;371(5):424-33
    • (2014) N Engl J Med , vol.371 , Issue.5 , pp. 424-433
    • Beer, T.M.1    Armstrong, A.J.2    De Rathkopf3
  • 41
    • 84899969509 scopus 로고    scopus 로고
    • Enzalutamide monotherpy in hormone-naive prostate cancer: Primary analysis of an open-label, single-arm, phase 2 study
    • Tombal B, Borre M, Rathenborg P, et al. Enzalutamide monotherpy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study. Lancet Oncol 2014;15(6):592-600.
    • (2014) Lancet Oncol , vol.15 , Issue.6 , pp. 592-600
    • Tombal, B.1    Borre, M.2    Rathenborg, P.3
  • 42
    • 84865345095 scopus 로고    scopus 로고
    • Tamoxifen for the management of breast events induced by non-steroidal antiandrogens in patients with prostate cancer: A systematic review
    • Kunath F, Keck B, Antes G, et al. Tamoxifen for the management of breast events induced by non-steroidal antiandrogens in patients with prostate cancer: a systematic review. BMC Med 2012;10:96
    • (2012) BMC Med , vol.10 , pp. 96
    • Kunath, F.1    Keck, B.2    Antes, G.3
  • 43
    • 0000500398 scopus 로고    scopus 로고
    • Bicalutamide (CasodexTM) versus combined androgen blockade (CAB): Open French multicentre study in patients with metastatic prostate cancer [abstract 1111]
    • Chatelain C, Fourcade RO, Delchambre J. Bicalutamide (CasodexTM) versus combined androgen blockade (CAB): open French multicentre study in patients with metastatic prostate cancer [abstract 1111]. Br J Urol 1997;80(Suppl 2):283
    • (1997) Br J Urol , vol.80 , pp. 283
    • Chatelain, C.1    Fourcade, R.O.2    Delchambre, J.3
  • 44
    • 77950217230 scopus 로고    scopus 로고
    • Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: Final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years
    • Iversen P, McLeod DG, See WA, et al. Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years. BJU Int 2010;105(8):1074-81
    • (2010) BJU Int , vol.105 , Issue.8 , pp. 1074-1081
    • Iversen, P.1    McLeod, D.G.2    See, W.A.3
  • 45
    • 20044376091 scopus 로고    scopus 로고
    • Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer
    • Boccardo F, Rubagotti A, Battaglia M, et al. Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer. J Clin Oncol 2005;23:808-15
    • (2005) J Clin Oncol , vol.23 , pp. 808-815
    • Boccardo, F.1    Rubagotti, A.2    Battaglia, M.3
  • 46
    • 17844367225 scopus 로고    scopus 로고
    • Prevention and management of bicalutamide-induced gynecomastia and breast pain: Randomized endocrinologic and clinical studies with tamoxifen and anastrozole
    • Saltzstein D, Sieber P, Morris T, Gallo J. Prevention and management of bicalutamide-induced gynecomastia and breast pain: randomized endocrinologic and clinical studies with tamoxifen and anastrozole. Prostate Cancer Prostatic Dis 2005;8(1):75-83
    • (2005) Prostate Cancer Prostatic Dis , vol.8 , Issue.1 , pp. 75-83
    • Saltzstein, D.1    Sieber, P.2    Morris, T.3    Gallo, J.4
  • 47
    • 72149085457 scopus 로고    scopus 로고
    • An open, randomised, multicentre, phase 3 trial comparing the efficacy of two tamoxifen schedules in preventing gynaecomastia induced by bicalutamide monotherapy in prostate cancer patients
    • Bedognetti D, Rubagotti A, Conti G, et al. An open, randomised, multicentre, phase 3 trial comparing the efficacy of two tamoxifen schedules in preventing gynaecomastia induced by bicalutamide monotherapy in prostate cancer patients. Eur Urol 2010;57(2):238-45
    • (2010) Eur Urol , vol.57 , Issue.2 , pp. 238-245
    • Bedognetti, D.1    Rubagotti, A.2    Conti, G.3
  • 48
    • 0031049759 scopus 로고    scopus 로고
    • Antiandrogen monotherapy in the management of advanced prostate cancer
    • Kaisary AV. Antiandrogen monotherapy in the management of advanced prostate cancer. Eur Urol 1997;31(Suppl 2):14-19
    • (1997) Eur Urol , vol.31 , pp. 14-19
    • Kaisary, A.V.1
  • 49
    • 0026338475 scopus 로고
    • Monotherapy with nilutamide, a pure nonsteroidal antiandrogen, in untreated patients with metastatic carcinoma of the prostate
    • Decensi AU, Boccardo F, Guarneri D, et al. Monotherapy with nilutamide, a pure nonsteroidal antiandrogen, in untreated patients with metastatic carcinoma of the prostate. J Urol 1991;146:377-81.
    • (1991) J Urol , vol.146 , pp. 377-381
    • Decensi, A.U.1    Boccardo, F.2    Guarneri, D.3
  • 50
    • 45849106157 scopus 로고    scopus 로고
    • Bicalutamide alone prior to brachytherapy achieves cytoreduction that is similar to luteinizing hormonereleasing hormone analogues with less patient-reported morbidity
    • Petit JH, Gluck C, Kiger WS III, et al. Bicalutamide alone prior to brachytherapy achieves cytoreduction that is similar to luteinizing hormonereleasing hormone analogues with less patient-reported morbidity. Urol Oncol 2008;26(4):372-7
    • (2008) Urol Oncol , vol.26 , Issue.4 , pp. 372-377
    • Petit, J.H.1    Gluck, C.2    Kiger, W.S.3
  • 51
    • 0030726889 scopus 로고    scopus 로고
    • Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma
    • Boccon-Gibod L, Fournier G, Bottet P, et al. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma. Eur Urol 1997;32(4):391-5
    • (1997) Eur Urol , vol.32 , Issue.4 , pp. 391-395
    • Boccon-Gibod, L.1    Fournier, G.2    Bottet, P.3
  • 52
    • 17144459258 scopus 로고    scopus 로고
    • Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the European Organization for Research and Treatment of Cancer (EORTC) Protocol 30892
    • Schröder FH, Whelan P, de Reijke TM, et al. Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the "European Organization for Research and Treatment of Cancer" (EORTC) Protocol 30892. Eur Urol 2004;45(4):457-64.
    • (2004) Eur Urol , vol.45 , Issue.4 , pp. 457-464
    • Schröder, F.H.1    Whelan, P.2    De Reijke, T.M.3
  • 53
    • 1242338036 scopus 로고    scopus 로고
    • Prospective randomized trial comparing flutamide as adjuvant treatment versus observation after radical prostatectomy for locally advanced, lymph node-negative prostate cancer
    • Wirth MP, Weissbach L, Marx FJ, et al. Prospective randomized trial comparing flutamide as adjuvant treatment versus observation after radical prostatectomy for locally advanced, lymph node-negative prostate cancer. Eur Urol 2004;45(3):267-70
    • (2004) Eur Urol , vol.45 , Issue.3 , pp. 267-270
    • Wirth, M.P.1    Weissbach, L.2    Marx, F.J.3
  • 54
    • 0347759859 scopus 로고    scopus 로고
    • Direct gastrointestinal toxicity of flutamide: Comparison of irradiated and non-irradiated cases
    • Langenstroer P, Porter HJ II, McLeod DG, Thrasher JB. Direct gastrointestinal toxicity of flutamide: comparison of irradiated and non-irradiated cases. J Urol 2004;171(2 Pt 1):684-6
    • (2004) J Urol , vol.171 , Issue.2 , pp. 684-686
    • Langenstroer, P.1    Porter, H.J.2    McLeod, D.G.3    Thrasher, J.B.4
  • 55
    • 0024326475 scopus 로고
    • Flutamide-induced diarrhea secondary to lactose intolerance
    • Yagoda A. Flutamide-induced diarrhea secondary to lactose intolerance. J Natl Cancer Inst 1989;81:1839
    • (1989) J Natl Cancer Inst , vol.81 , pp. 1839
    • Yagoda, A.1
  • 56
    • 0027155356 scopus 로고
    • Goserelin acetate with or without flutamide in the treatment of patients with locally advanced or metastatic prostate cancer. The Italian Prostatic Cancer Project (PONCAP) Study Group
    • Boccardo F, Pace M, Rubagotti A, et al. Goserelin acetate with or without flutamide in the treatment of patients with locally advanced or metastatic prostate cancer. The Italian Prostatic Cancer Project (PONCAP) Study Group. Eur J Cancer 1993;29A(8):1088-93
    • (1993) Eur J Cancer , vol.29 A , Issue.8 , pp. 1088-1093
    • Boccardo, F.1    Pace, M.2    Rubagotti, A.3
  • 57
    • 0025604473 scopus 로고
    • Zoladex plus flutamide vs orchidectomy for advanced prostatic cancer. Danish Prostatic Cancer Group (DAPROCA)
    • Iversen P. Zoladex plus flutamide vs orchidectomy for advanced prostatic cancer. Danish Prostatic Cancer Group (DAPROCA). Eur Urol 1990;18(Suppl 3):41-4
    • (1990) Eur Urol , vol.18 , pp. 41-44
    • Iversen, P.1
  • 58
    • 0031907685 scopus 로고    scopus 로고
    • Maximal androgen blockade: Final analysis of EORTC phase III trial 30853. EORTC Genito-Urinary Tract Cancer Cooperative Group and the EORTC Data Center
    • Denis LJ, Keuppens F, Smith PH, et al. Maximal androgen blockade: final analysis of EORTC phase III trial 30853. EORTC Genito-Urinary Tract Cancer Cooperative Group and the EORTC Data Center. Eur Urol 1998;33(2):144-51
    • (1998) Eur Urol , vol.33 , Issue.2 , pp. 144-151
    • Denis, L.J.1    Keuppens, F.2    Smith, P.H.3
  • 59
    • 0028240927 scopus 로고
    • Toxicity of the antiandrogen flutamide in isolated rat hepatocytes
    • Fau D, Eugene D, Berson A, et al. Toxicity of the antiandrogen flutamide in isolated rat hepatocytes. J Pharmacol Exp Ther 1994;269(3):954-62
    • (1994) J Pharmacol Exp Ther , vol.269 , Issue.3 , pp. 954-962
    • Fau, D.1    Eugene, D.2    Berson, A.3
  • 60
    • 34147151302 scopus 로고    scopus 로고
    • Involvement of bile salt export pump in flutamide-induced cholestatic hepatitis
    • Iwanaga T, Nakakariya M, Yabuuchi H, et al. Involvement of bile salt export pump in flutamide-induced cholestatic hepatitis. Biol Pharm Bull 2007;30(4):739-44
    • (2007) Biol Pharm Bull , vol.30 , Issue.4 , pp. 739-744
    • Iwanaga, T.1    Nakakariya, M.2    Yabuuchi, H.3
  • 61
    • 10844234635 scopus 로고    scopus 로고
    • Hepatotoxicity induced by antiandrogens: A review of the literature
    • Thole Z, Manso G, Salgueiro E, et al. Hepatotoxicity induced by antiandrogens: a review of the literature. Urol Int 2004;73(4):289-95
    • (2004) Urol Int , vol.73 , Issue.4 , pp. 289-295
    • Thole, Z.1    Manso, G.2    Salgueiro, E.3
  • 62
    • 0026285040 scopus 로고
    • Anandron (RU 23908) in metastatic prostate cancer: Preliminary results of a multicentric Italian study
    • Boccardo F, Decensi AU, Guarneri D, et al. Anandron (RU 23908) in metastatic prostate cancer: preliminary results of a multicentric Italian study. Cancer Detect Prev 1991;15(6):501-3
    • (1991) Cancer Detect Prev , vol.15 , Issue.6 , pp. 501-503
    • Boccardo, F.1    Decensi, A.U.2    Guarneri, D.3
  • 63
    • 0030915668 scopus 로고    scopus 로고
    • Long-term efficacy and safety of nilutamide plus castration in advanced prostate cancer, and the significance of early prostate specific antigen normalization. International Anandron Study Group
    • Dijkman GA, Janknegt RA, De Reijke TM, Debruyne FM. Long-term efficacy and safety of nilutamide plus castration in advanced prostate cancer, and the significance of early prostate specific antigen normalization. International Anandron Study Group. J Urol 1997;158(1):160-3
    • (1997) J Urol , vol.158 , Issue.1 , pp. 160-163
    • Dijkman, G.A.1    Janknegt, R.A.2    De Reijke, T.M.3    Debruyne, F.M.4
  • 64
  • 65
    • 0027356895 scopus 로고
    • A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer
    • Harris MG, Coleman SG, Faulds D, Chrisp P. Nilutamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer. Drugs Aging 1993;3(1):9-25
    • (1993) Drugs Aging , vol.3 , Issue.1 , pp. 9-25
    • Harris, M.G.1    Coleman, S.G.2    Faulds, D.3    Nilutamide, C.P.4
  • 66
    • 33746911141 scopus 로고    scopus 로고
    • Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration
    • Tyrrell CJ, Iversen P, Tammela T, et al. Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration. BJU Int 2006;98(3):563-72.
    • (2006) BJU Int , vol.98 , Issue.3 , pp. 563-572
    • Tyrrell, C.J.1    Iversen, P.2    Tammela, T.3
  • 67
    • 0035670516 scopus 로고    scopus 로고
    • Is there a role for antiandrogen monotherapy in patients with metastatic prostate cancer?
    • Kaisary AV, Iversen P, Tyrrell CJ, et al. Is there a role for antiandrogen monotherapy in patients with metastatic prostate cancer? Prostate Cancer Prostatic Dis 2001;4(4):196-203
    • (2001) Prostate Cancer Prostatic Dis , vol.4 , Issue.4 , pp. 196-203
    • Kaisary, A.V.1    Iversen, P.2    Tyrrell, C.J.3
  • 68
    • 0031024321 scopus 로고    scopus 로고
    • Fulminant hepatic failure associated with bicalutamide
    • Dawson LA, Chow E, Morton G. Fulminant hepatic failure associated with bicalutamide. Urology 1997;49:283-4
    • (1997) Urology , vol.49 , pp. 283-284
    • Dawson, L.A.1    Chow, E.2    Morton, G.3
  • 69
    • 84855204773 scopus 로고    scopus 로고
    • Interstitial pneumonitis induced by bicalutamide given for prostate cancer
    • Masago T, Watanabe T, Nemoto R, Motoda K. Interstitial pneumonitis induced by bicalutamide given for prostate cancer. Int J Clin Oncol 2011;16(6):763-5
    • (2011) Int J Clin Oncol , vol.16 , Issue.6 , pp. 763-765
    • Masago, T.1    Watanabe, T.2    Nemoto, R.3    Motoda, K.4
  • 70
    • 7444242095 scopus 로고    scopus 로고
    • Bicalutamide: Clinical pharmacokinetics and metabolism
    • Cockshott ID. Bicalutamide: clinical pharmacokinetics and metabolism. Clin Pharmacokinet 2004;43(13):855-78
    • (2004) Clin Pharmacokinet , vol.43 , Issue.13 , pp. 855-878
    • Cockshott, I.D.1
  • 71
    • 33845580082 scopus 로고    scopus 로고
    • Antiandrogens in the treatment of prostate cancer
    • Wirth MP, Hakenberg OW, Froehner M. Antiandrogens in the treatment of prostate cancer. Eur Urol 2007;51(2):306-13
    • (2007) Eur Urol , vol.51 , Issue.2 , pp. 306-313
    • Wirth, M.P.1    Hakenberg, O.W.2    Froehner, M.3
  • 72
    • 77952105685 scopus 로고    scopus 로고
    • Antitumour activity of MDV3100 in castration-resistant prostate cancer: A phase 1-2 study
    • Scher HI, Beer TM, Higano CS, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010;375(9724):1437-46
    • (2010) Lancet , vol.375 , Issue.9724 , pp. 1437-1446
    • Scher, H.I.1    Beer, T.M.2    Higano, C.S.3
  • 73
    • 79951518634 scopus 로고    scopus 로고
    • Drug safety is a barrier to the discovery and development of new androgen receptor antagonists
    • Foster WR, Car BD, Shi H, et al. Drug safety is a barrier to the discovery and development of new androgen receptor antagonists. Prostate 2011;71:480-8
    • (2011) Prostate , vol.71 , pp. 480-488
    • Foster, W.R.1    Car, B.D.2    Shi, H.3
  • 74
    • 84893349290 scopus 로고    scopus 로고
    • Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: Results from the phase III AFFIRM trial
    • Sternberg CN, de Bono JS, Chi KN, et al. Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial. Ann Oncol 2014;25(2):429-34
    • (2014) Ann Oncol , vol.25 , Issue.2 , pp. 429-434
    • Sternberg, C.N.1    De Bono, J.S.2    Chi, K.N.3
  • 75
    • 84899409581 scopus 로고    scopus 로고
    • Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment
    • Badrising S, van der Noort V, van Oort IM, et al. Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment. Cancer 2014;120(7):968-75
    • (2014) Cancer , vol.120 , Issue.7 , pp. 968-975
    • Badrising, S.1    Van Der Noort, V.2    Van Oort, I.M.3
  • 76
    • 84888852048 scopus 로고    scopus 로고
    • Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone
    • Schrader AJ, Boegemann M, Ohlmann CH, et al. Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone. Eur Urol 2014;65(1):30-6
    • (2014) Eur Urol , vol.65 , Issue.1 , pp. 30-36
    • Schrader, A.J.1    Boegemann, M.2    Ohlmann, C.H.3
  • 77
    • 84863230424 scopus 로고    scopus 로고
    • ARN-509: A novel antiandrogen for prostate cancer treatment
    • Clegg NJ, Wongvipat J, Joseph JD, et al. ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res 2012;72(6):1494-503
    • (2012) Cancer Res , vol.72 , Issue.6 , pp. 1494-1503
    • Clegg, N.J.1    Wongvipat, J.2    Joseph, J.D.3
  • 78
    • 84858055379 scopus 로고    scopus 로고
    • Impact of androgen deprivation therapy on sexual function
    • Mazzola CR, Mulhall JP. Impact of androgen deprivation therapy on sexual function. Asian J Androl 2012;14:198-203
    • (2012) Asian J Androl , vol.14 , pp. 198-203
    • Mazzola, C.R.1    Mulhall, J.P.2
  • 79
    • 84881670047 scopus 로고    scopus 로고
    • The effect of estrogen on the sexual interest of castrated males: Implications to prostate cancer patients on androgen-deprivation therapy
    • Wibowo E, Wassersug RJ. The effect of estrogen on the sexual interest of castrated males: implications to prostate cancer patients on androgen-deprivation therapy. Crit Rev Oncol Hematol 2013;87(3):224-38
    • (2013) Crit Rev Oncol Hematol , vol.87 , Issue.3 , pp. 224-238
    • Wibowo, E.1    Wassersug, R.J.2
  • 80
    • 0032831590 scopus 로고    scopus 로고
    • Quality of life issues relating to endocrine treatment options
    • Iversen P. Quality of life issues relating to endocrine treatment options. Eur Urol 1999;36(Suppl 2):20-6
    • (1999) Eur Urol , vol.36 , pp. 20-26
    • Iversen, P.1
  • 81
    • 72149087677 scopus 로고    scopus 로고
    • Managing hot flushes in men after prostate cancer: A systematic review
    • Frisk J. Managing hot flushes in men after prostate cancer: a systematic review. Maturitas 2010;65(1):15-22
    • (2010) Maturitas , vol.65 , Issue.1 , pp. 15-22
    • Frisk, J.1
  • 83
    • 63249123610 scopus 로고    scopus 로고
    • Anaemia following initiation of androgen deprivation therapy for metastatic prostate cancer: A retrospective chart review
    • Curtis KK, Adam TJ, Chen SC, et al. Anaemia following initiation of androgen deprivation therapy for metastatic prostate cancer: a retrospective chart review. Aging Male 2008;11(4):157-61
    • (2008) Aging Male , vol.11 , Issue.4 , pp. 157-161
    • Curtis, K.K.1    Adam, T.J.2    Chen, S.C.3
  • 84
    • 3142634522 scopus 로고    scopus 로고
    • Testosterone's metabolism in the hippocampus may mediate its anti-anxiety effects in male rats
    • Frye CA, Edinger KL. Testosterone's metabolism in the hippocampus may mediate its anti-anxiety effects in male rats. Pharmacol Biochem Behav 2004;78:473-81
    • (2004) Pharmacol Biochem Behav , vol.78 , pp. 473-481
    • Frye, C.A.1    Edinger, K.L.2
  • 85
    • 0036968877 scopus 로고    scopus 로고
    • Altered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing hormone analogues and cyproterone acetate: A randomized controlled trial
    • Green HJ, Pakenham KI, Headley BC, et al. Altered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing hormone analogues and cyproterone acetate: a randomized controlled trial. BJU Int 2002;90(4):427-32
    • (2002) BJU Int , vol.90 , Issue.4 , pp. 427-432
    • Green, H.J.1    Pakenham, K.I.2    Headley, B.C.3
  • 86
    • 2542534543 scopus 로고    scopus 로고
    • Quality of life compared during pharmacological treatments and clinical monitoring for non-localized prostate cancer: A randomized controlled trial
    • Green HJ, Pakenham KI, Headley BC, et al. Quality of life compared during pharmacological treatments and clinical monitoring for non-localized prostate cancer: a randomized controlled trial. BJU Int 2004;93(7):975-9
    • (2004) BJU Int , vol.93 , Issue.7 , pp. 975-979
    • Green, H.J.1    Pakenham, K.I.2    Headley, B.C.3
  • 87
    • 38049161524 scopus 로고    scopus 로고
    • Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: What do we really know?
    • Higano CS. Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really know? Nat Clin Pract Urol 2008;5(1):24-34
    • (2008) Nat Clin Pract Urol , vol.5 , Issue.1 , pp. 24-34
    • Higano, C.S.1
  • 89
    • 69249090994 scopus 로고    scopus 로고
    • Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values
    • Wadhwa VK, Weston R, Mistry R, Parr NJ. Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values. BJU Int 2009;104(6):800-5
    • (2009) BJU Int , vol.104 , Issue.6 , pp. 800-805
    • Wadhwa, V.K.1    Weston, R.2    Mistry, R.3    Parr, N.J.4
  • 90
    • 33751396873 scopus 로고    scopus 로고
    • A selective androgen receptor modulator that reduces prostate tumor size and prevents orchidectomy-induced bone loss in rats
    • Allan G, Lai MT, Sbriscia T, et al. A selective androgen receptor modulator that reduces prostate tumor size and prevents orchidectomy-induced bone loss in rats. J Steroid Biochem Mol Biol 2007;103(1):76-83
    • (2007) J Steroid Biochem Mol Biol , vol.103 , Issue.1 , pp. 76-83
    • Allan, G.1    Lai, M.T.2    Sbriscia, T.3
  • 91
    • 33749058933 scopus 로고    scopus 로고
    • Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer
    • Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006;24(27):4448-56.
    • (2006) J Clin Oncol , vol.24 , Issue.27 , pp. 4448-4456
    • Keating, N.L.1    O'Malley, A.J.2    Smith, M.R.3
  • 92
    • 24144489427 scopus 로고    scopus 로고
    • Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: A meta-analysis
    • Isidori AM, Giannetta E, Greco EA, et al. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol (Oxf) 2005;63(3):280-93
    • (2005) Clin Endocrinol (Oxf) , vol.63 , Issue.3 , pp. 280-293
    • Isidori, A.M.1    Giannetta, E.2    Greco, E.A.3
  • 93
    • 18844376325 scopus 로고    scopus 로고
    • Endogenous sex hormones and metabolic syndrome in aging men
    • Muller M, Grobbee DE, den Tonkelaar I, et al. Endogenous sex hormones and metabolic syndrome in aging men. J Clin Endocrinol Metab 2005;5):2618-23
    • (2005) J Clin Endocrinol Metab , vol.5 , pp. 2618-2623
    • Muller, M.1    De Grobbee2    Den Tonkelaar, I.3
  • 94
    • 33748474608 scopus 로고    scopus 로고
    • Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy
    • Braga-Basaria M, Dobs AS, Muller DC, et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol 2006;24(24):3979-83
    • (2006) J Clin Oncol , vol.24 , Issue.24 , pp. 3979-3983
    • Braga-Basaria, M.1    Dobs, A.S.2    Muller, D.C.3
  • 95
    • 35148842094 scopus 로고    scopus 로고
    • Risk of new-onset diabetes mellitus and worsening glycaemic variables for established diabetes in men undergoing androgen-deprivation therapy for prostate cancer
    • Derweesh IH, Diblasio CJ, Kincade MC, et al. Risk of new-onset diabetes mellitus and worsening glycaemic variables for established diabetes in men undergoing androgen-deprivation therapy for prostate cancer. BJU Int 2007;100(5):1060-5
    • (2007) BJU Int , vol.100 , Issue.5 , pp. 1060-1065
    • Derweesh, I.H.1    Diblasio, C.J.2    Kincade, M.C.3
  • 96
    • 83055163746 scopus 로고    scopus 로고
    • Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: A meta-analysis of randomized trials
    • Nguyen PL, Je Y, Schutz FA, et al. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA 2011;306(21):2359-66
    • (2011) JAMA , vol.306 , Issue.21 , pp. 2359-2366
    • Nguyen, P.L.1    Je, Y.2    Schutz, F.A.3
  • 97
    • 33749539357 scopus 로고    scopus 로고
    • The rising prevalence of androgen deprivation among older American men since the advent of prostate-specific antigen testing: A population-based cohort study
    • Barry MJ, Delorenzo MA, Walker-Corkery ES, et al. The rising prevalence of androgen deprivation among older American men since the advent of prostate-specific antigen testing: a population-based cohort study. BJU Int 2006;98(5):973-8
    • (2006) BJU Int , vol.98 , Issue.5 , pp. 973-978
    • Barry, M.J.1    Delorenzo, M.A.2    Walker-Corkery, E.S.3
  • 98
    • 36949026378 scopus 로고    scopus 로고
    • Anti-androgens increase N-terminal pro-BNP levels in men with prostate cancer
    • Dockery F, Bulpitt CJ, Agarwal S, et al. Anti-androgens increase N-terminal pro-BNP levels in men with prostate cancer. Clin Endocrinol (Oxf) 2008;68(1):59-6
    • (2008) Clin Endocrinol (Oxf) , vol.68 , Issue.1 , pp. 59-66
    • Dockery, F.1    Bulpitt, C.J.2    Agarwal, S.3
  • 99
    • 74049152290 scopus 로고    scopus 로고
    • Diabetes and cardiovascular disease during androgen deprivation therapy: Observational study of veterans with prostate cancer
    • Keating NL, O'Malley AJ, Freedland SJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst 2010;102(1):39-46
    • (2010) J Natl Cancer Inst , vol.102 , Issue.1 , pp. 39-46
    • Keating, N.L.1    O'Malley, A.J.2    Freedland, S.J.3    Smith, M.R.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.